ABSTRACT
As surgical efforts to remove all visible disease have increased, splenectomy has become an integral part of achieving complete cytoreduction. Splenic metastases have been reported in 20% of patients with advanced ovarian cancer ( Rose et al. 1989 ). Splenic involvement can be classified as parenchymal, hilar, and/or capsular. Numerous authors have reported undertaking splenectomy in the context of both primary and secondary cytoreductive surgery for EOC.
